

## INDEX

Note: UC stands for Ulcerative Colitis. Page numbers in *italics* indicate figures. Page numbers followed by a “t” indicate tables.

- Abatacept, 186
- Abdominal pain, 46t
- ACG. *See American College of Gastroenterology (ACG).*
- Activity Index, 39, 40t
- Acupuncture, 218-219
- Acute severe UC, management of, 95, 107t-108t
- Adalimumab (Humira), 93, 161t, 174-178
- action mechanism, 163-164, 165
- site of action, 26
- biosimilars, 201
- Amjevita, 201
- Cyltezo, 201
- Hadlima, 201
- dosage and administration, 161t, 178
- efficacy, 175-176, 176
- FDA approval, 174
- indications for, 93, 163, 174
- safety, 176-178, 177t
- infections, 161t, 177t, 178
- injection-site reaction, 176, 177t
- malignancy, 161t, 177t, 178
- warnings and precautions, 161t
- usages, ACG recommendations, 100t, 101t
- Adaptive immunity, 25-28
- Age
- at diagnosis, 16-17, 17
- prognosis and, 39
- differences in clinical presentation, 41
- IBD prevalence and, 9-10
- UC patients, 16-17, 17
- Albumen (hypoalbuminemia), 46t, 60
- Amebic colitis/dysentery, 56, 58t
- American College of Gastroenterology (ACG)
- guidelines for UC in adults (2019), 96, 97t-109t
- recommendations for health maintenance, 228t-229t
- website, 241t
- American Gastroenterological Association, 241t
- American Society of Colon and Rectal Surgeons, 241t
- Aminosalicylate (5-ASA) therapy, 111-124
- action mechanism, 111, 114-115
- bacteria-dependent activation, 112, 114
- adverse reactions, 91, 111, 113, 122
- combination therapy, 93, 99t
- efficacy, 120-121
- indications for, 91-92, 111, 113, 116t-119t, 120-122
- as initial treatment option, 91, 111, 122, 125
- for mild to moderate UC, 90, 91-92, 97t-99t
- for moderate to severe UC, 106t-107t
- oral agents, 120-121
- rectal agents, 121
- in step-up approach to treatment, 90
- patient compliance and, 113-120
- safety, 120-122
- types of agents, 111-120, 114-115, 116t-119t
- balsalazide, 91, 112, 114, 117t
- FDA-approved, 112, 116t-119t
- mesalamine, 91, 112, 115, 117t-119t
- olsalazine, 91, 112, 114, 116t
- sulfasalazine, 91, 111-112, 114, 116t
- usage and dosages, 97t-99t, 113, 116t-119t
- ACG recommendations, 97t-99t, 101t, 106t-107t
- changing to a different formulation, 98t
- for left-sided colitis, 91, 97t-98t
- for proctitis, 91, 97t
- Amjevita (adalimumab biosimilar), 201
- Anakinra, 186
- ANCA (anti-neutrophil cytoplasmic antibody), 46t, 60
- Andrographis paniculate*, 218
- Anemia, 73t-74t, 85
- in children, 43
- iron deficiency, 46t, 60, 74t, 85
- macrocytic megaloblastic, 74t, 85
- treatment, 73t-74t, 85
- Ankylosing spondylitis (AS), 69, 77
- Anti-neutrophil cytoplasmic antibody (ANCA), 46t, 60
- Anti-*Saccharomyces cerevisiae* antibody (ASCA), 60
- Antibiotics, ACG recommendations, 102t
- Antibodies
- ANCA (anti-neutrophil cytoplasmic antibody), 46t, 80
- antibody testing, ACG recommendations, 97t, 101t
- ASCA (anti-*Saccharomyces cerevisiae* antibody), 60
- autoantibodies, 46t

- in primary sclerosing cholangitis, 81
  - EIMs and, 76
- Anxiety, 34
  - screening patients for, 105t
- Aphthous stomatitis, 71t, 79, 80
  - in children, 43
  - incidence of, 42, 77, 79
- Appendectomy, as protective factor, 31
- Apriso (oral mesalamine), 112, 115, 117t, 120
- Arthritis/arthropathies, 42, 70t, 77
  - axial arthropathies, 70t, 77
  - in children, 43
  - peripheral arthropathies, 70t, 77
- Asacol HD (oral mesalamine), 112, 115, 117t
- ASCA (anti-*Saccharomyces cerevisiae* antibody), 60
- Autoantibodies, 46t
- Avsola (infliximab biosimilar), 200
- Azathioprine, 136t, 147-149
- Azulfidine/Azulfidine EN (sulfasalazine), 114, 116t
  
- Backwash ileitis, 62
- Bacteria. See *Gut bacteria; Microbes; specific bacteria.*
- Bacterial colitis, 56, 58t
- Balsalazide, 91, 112, 114, 117t
  - Colazal, 112, 113, 114, 117t
  - Giazo, 112, 114, 117t
- Barrier integrity, 23, 26
- Beclomethasone dipropionate, 126
- Bile ducts, 81, 82-84
- Biologics, 159-202. See also *specific agents.*
  - action mechanisms, 159
  - agent classes
    - integrin  $\alpha 4\beta 7$  blockers, 187-195
    - interleukin-12/23 antagonists, 195-200
    - TNF blockers, 93-94, 163-187
  - agents (FDA-approved), 93-94, 159, 160t-162t
    - adalimumab (Humira), 93, 174-178
    - golimumab (Simponi), 93-94, 178-182
    - infliximab (Remicade), 94, 164-174
    - ustekinumab (Stelara), 94, 195-200
    - vedolizumab (Entyvio), 94, 187-195
  - biosimilars, 200-201
  - drugs in development, 201
  - indications for, 93-94, 159-163
- Biologics, *continued*
  - risks and boxed warnings, 160t-162t, 163, 182-187
  - surgery rates potentially reduced by, 204
  - usages, 160t-162t
    - ACG recommendations, 100t-101t
    - in step-up approach to treatment, 90
- Biopsies, 62
  - ACG statement on, 104t
  - for colorectal cancer, 108t
  - for cytomegalovirus colitis, 107t
- Biosimilars, 200-201
- Bleeding
  - rectal, 46t
    - Mayo score and, 48, 49
    - UCEIS scoring, 52-54
- Blood pressure screening, 236
- Bone manifestations/complications, 74t, 85-86
  - DEXA scanning, 235
  - fracture risk, 85, 231
  - low bone mineral density, 74t, 85, 231-236
  - osteonecrosis, 74t
  - osteopenia, 74t, 235
  - osteoporosis, 74t, 85-86, 231-236
- Bowel rest, suggestion against total parenteral nutrition for purpose of, 102t
- Breastfeeding, 34
- Budesonide (Uceris), 126, 128-129
  - budesonide MMX, 128-129
    - in combination with 5-ASA, 99t
    - usages, 128
      - ACG recommendations, 99t, 106t, 107t
      - for left-sided colitis, 92, 98t
      - for moderate to severe disease, 93, 99t, 106t, 107t
      - in step-up approach to treatment, 90
  - efficacy, 128-129, 130t, 131t
  - FDA approval of, 128
  - formulations
    - rectal foam, 129, 131t
    - tablet formulation, 128-129, 130t
- C-reactive protein (CRP), 59, 107t
- Calcineurin inhibitor. See *Tacrolimus.*
- Calprotectin, fecal, 46t, 59, 90, 97t, 104t
- Canasa (rectal mesalamine), 112, 113, 115, 118t

- Cancer, 238-240. See also *Colorectal cancer*.  
 cervical cancer, 239  
 colorectal cancer, 238-239  
   as indication for surgery, 96, 205t, 206  
   prevention in UC, 103t, 108t-109t  
   primary sclerosing cholangitis (PSC) and, 42, 238  
 screening for, 238-240  
 skin cancer, 239-240
- Categories of disease extent, 104t. See also *Extent of disease*.
- Certolizumab pegol, site of action, 26
- Cervical cancer screening, 239
- Children. See also *Pediatric patients*.  
 clinical presentation in, 41  
 extraintestinal manifestations in, 43, 76  
 PUCAI (Pediatric Ulcerative Colitis Activity Index), 41, 56, 57t
- Chromoendoscopy, 103t, 108t, 238-239
- Classification systems for UC, 45-56  
 Mayo score, 47-55, 49-51  
 Montreal classification system, 38, 45-47, 47t, 48t  
 other severity indices, 55-56  
 Paris classification system, 46-47, 48t  
 Pediatric Ulcerative Colitis Activity Index (PUCAI), 56, 57t  
 Rome classification system, 45  
 Simple Clinical Colitis Activity Index, 56  
 Ulcerative Colitis Endoscopic Index of Severity (UCEIS), 51-55, 52-54  
 Vienna classification system, 45
- Clinical presentation, 37-44  
 ACG UC Activity Index, 39, 40t  
 age-related differences in, 41  
 disease progression and, 37, 39  
 extraintestinal manifestations, 42-43  
 left-sided colitis, 37, 38  
 pancolitis, 37  
 pediatric patients, atypical features in, 62-63  
 proctosigmoiditis, 37, 38  
 prognosis, 39-41  
 severity and extent, 37-39, 38  
 ulcerative proctitis, 37, 38
- Clostridium difficile*, 33, 90  
 differential diagnosis, 56, 58t  
 in hospital settings, testing for, 102t  
 treatment with fecal microbiota transplant, 211, 212-214  
 treatment with vancomycin, 102t
- Colazal (balsalazide), 112, 113, 114, 117t
- Colectomy, 206-208. See also *Surgery*.  
 for refractory or nonresponsive disease, 106t, 203, 204, 205t  
 in step-up approach to treatment, 90  
 timing of evaluation for, 95
- Colitis  
 differential diagnosis of, 56-59, 58t  
 EIMs and, 75  
 extensive, 92  
 ischemic, 56, 58t  
 left-sided. See *Left-sided colitis*.  
 pancolitis, 37  
 parasite-induced, 56, 58t
- Colonocytes, 23, 26  
 barrier integrity and, 23
- Colonoscopy. See also *Endoscopy*.  
 ACG concept statement on, 104t  
 for assessment of response to treatment, 90  
 for patient assessment, 89-90, 104t  
 screening and surveillance for colorectal cancer, 103t, 108t, 238
- Colorectal cancer, 238-239  
 exercise, benefits for, 220  
 prevention of, 103t, 108t-109t  
 primary sclerosing cholangitis (PSC) and, 42, 238  
 surgery for, 96, 205t, 206
- Colorectal cancer prevention in UC, 103t, 108t-109t  
 biopsies, 108t  
 CT colonography (not recommended), 109t  
 dye spray chromoendoscopy, 103t, 109t  
 dysplasia, 108t  
 fecal DNA testing (not recommended), 109t  
 frequency of screening and monitoring, 108t  
 referral for surgery, 108t  
 review of findings, 108t  
 screening and surveillance colonoscopy, 103t, 108t, 238  
 white-light exams, 103t, 108t, 238
- Comorbidities, 69-88, 70t-74t  
 anemia, 73t-74t, 85  
 bone manifestations, 74t, 85-86  
 early diagnosis and treatment of, 69, 75, 76, 86  
 epidemiology of EIMs in UC and CD, 75  
 extraintestinal complications, 69, 70t-74t  
 extraintestinal manifestations (EIMs), 42-43, 69, 70t-74t  
 genetic factors and, 76

- hepatopancreatobiliary manifestations, 72t
- inflammation and, 75-76
- joint manifestations, 70t, 77
- mucocutaneous manifestations, 70t-71t, 77-79, 78-80
- musculoskeletal manifestations, 70t
- neurologic manifestations, 73t
- ocular manifestations, 71t, 79-80, 81
- osteoporosis, 74t, 85-86
- pathogenesis, 75-76
- primary sclerosing cholangitis (PSC), 80-83, 82-84
- pulmonary manifestations, 72t-73t
- quality of life and, 69, 86
- renal and urologic manifestations, 73t
- thromboembolic manifestations, 72t
- treatment of, 69, 70t-74t
- Complementary and alternative medicines (CAMs), 211-212, 214-219
  - acupuncture, massage therapy, and moxibustion, 218-219
  - cautions for, 214-215
    - drug-drug interactions, 214
    - reduced compliance with medical therapies, 214
  - curcumen (turmeric), 217-218
  - definition of alternative medicine, 211
  - definition of complementary medicine, 211
  - herbal agents, 218
  - probiotics, 215-217
  - traditional Chinese medicine (TCM), 218
- Compliance. *See Patient compliance.*
- Conjunctivitis, 79
- Constipation, 37-39
- Corticosteroids, 125-132
  - action mechanism, 125
  - adverse events, 92, 126, 127t
    - osteoporosis/osteopenia, 235
  - combination therapy, with 5-ASAs, 125
  - efficacy, 125-126
    - budesonide, 128-129, 130t, 131t
    - long-term efficacy, lack of, 92, 125
  - formulations, 125-126
    - budesonide (Uceris), 126, 128-129
    - IV steroids, 93, 95, 126
    - with minimal systemic activity, 126
    - prolonged-release beclomethasone dipropionate, 126
  - indications, 125-126
- Corticosteroids, *continued*
  - for left-sided colitis, 92
  - for mild to moderate disease, 90, 91-92, 98t
  - for moderate to severe disease, 90, 92-93, 99t, 106t
  - for proctitis, 91
  - safety, 127-128, 127t
  - steroid-sparing therapy, 107t
  - usages, 125-126
    - ACG recommendations, 98t-99t, 101t, 106t
    - in hospitalized patients, 102t
    - recommendation against systemics for maintenance, 99t, 101t
    - in step-up approach to treatment, 90
    - systemic therapy, 106t
- Costs of care, 10
- Course of UC, 37, 39
- Crohn's disease (CD), 9. *See also Comorbidities; Extraintestinal manifestations.*
  - development after IPAA surgery, 208
  - differential diagnosis, 56, 58t, 62
  - epidemiology, 9-29
  - extraintestinal manifestations in, 75, 77-79
    - mucocutaneous manifestations, 77-79
  - family history, 21-22
  - gender and, 18
  - genetic factors in, 21-22
  - incidence and prevalence of, 9-11, 12-15
  - non-contiguous inflammation in, 62
  - surgery rates for, 203-204
  - vs UC, 9
- Crohn's & Colitis Foundation, 241t
- CRP (C-Reactive Protein), 59
- Crypt architecture, 46t, 59
  - abscesses, 46t
- Curcumen (turmeric), 106t, 217-218
- Cyclosporine A, 107t, 136t-137t, 149-150
  - action mechanism, 149
  - efficacy, 150
  - indications for, 136t-137t, 149
    - acute severe disease, 95, 149
  - safety, 136t-137t, 150
  - usages, 136t-137t, 149-150
    - in hospitalized patients, 103t
    - in step-up approach to treatment, 90
- Cyltezo (adalimumab biosimilar), 201

- Cytokines, 24, 151
- Cytomegalovirus colitis, 107t
- Delzicol (oral mesalamine), 112, 113, 115, 118t
- Dendritic cells, 26-27
- Depression, 34, 236-237  
screening for, 105t, 236-237
- Developing nations, UC incidence in, 11, 22, 31
- Diagnosis and evaluation, 45-67, 46t, 89-90. See also *Clinical presentation*.
- ACG key concept statements, 104t
- ACG recommendations, 97t
- age at diagnosis, 16-17, 17
- biopsies, 62
- categories of disease extent (proctitis, left-sided colitis, extensive colitis), 104t
- classification systems, 45-67  
Mayo score, 47-55, 49-51  
Montreal classification system, 38, 45-47, 47t, 48t  
other severity indices, 55-56  
Paris classification system, 46-47, 48t  
Rome classification system, 45  
Ulcerative Colitis Endoscopic Index of Severity (UCEIS), 51-55, 52-54  
Vienna classification system, 45
- clinical features, 46t
- criteria for diagnosis, 46t
- differential diagnosis, 56-59, 58t
- endoscopic evaluation, 46t, 60-62, 61  
patchy disease or rectal sparing, 62  
histologic evaluation, 46t, 63, 64t-65t  
basal lymphoplasmacytosis, 63  
inflammatory cell infiltration of mucosa, 63, 64t-65t  
Nancy histological index, 64t  
Robarts histopathology index, 64t-65t
- key diagnostic features, 46t
- laboratory investigations, 46t, 59-60  
ANCA and ASCA, 46t, 60  
ESR and CRP, 59  
fecal calprotectin and lactoferrin, 59, 90, 97t, 104t
- pediatric patients, atypical features in, 62-63
- radiologic findings, 60
- unclassified inflammatory bowel disease (IBDU), 62
- Diarrhea, 46t
- Diet, risk and, 34
- Differential diagnosis, 56-59, 58t
- Dipentum (olsalazine), 112, 114, 116t
- Disease management based on clinical severity, 89-110.  
See also *Management of UC*.
- Dysbiosis, 25, 26, 212
- E. coli*, 213  
strain Nissle 1917 (EcN), 216-217
- EIMs. See *Extraintestinal manifestations (EIMs)*.
- Endoscopy, 60-62, 61, 238-239  
chromoendoscopy, 103t, 108t, 238-239  
diagnosis and, 46t, 60-62, 61  
endoscopic healing as a goal/end-point for treatment, 90, 105t  
for gastrointestinal involvement (upper GI), 104t  
Mayo score (endoscopic subscore), 48, 49, 50-51, 50-51  
monitoring and surveillance for colorectal cancer, 108t-109t  
monitoring remission with, 90, 105t  
for patient assessment, 89-90  
UC features on, 46t
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS), 51-55, 52-54  
upper endoscopy, 104t  
white-light endoscopy, 103t, 108t, 238
- Enemas, 98t, 112, 113  
with 5-ASAs, 91, 98t  
patient compliance issues, 91  
with Rowasa/SfRowasa (mesalamine), 112  
versus suppositories, 113, 114
- Entamoeba histolytica*, 56
- Entyvio. See *Vedolizumab (Entyvio)*.
- Environmental risk and protective factors, 22-23, 31, 31-35, 31-36  
diet, 34  
environmental factors in UC, 22-23  
microbial exposure: The Hygiene Hypothesis, 33  
occupation, 33  
other factors, 34  
tobacco smoking, 31-32, 231  
weight, 33-34
- Epidemiology, 9-29  
age and, 16-17, 17  
of EIMs in UC and CD, 75  
gender and, 17-18  
incidence and prevalence in North America, 9-10, 12, 14

- incidence and prevalence worldwide, 11, 12-15
- morbidity and mortality, 11-16
- racial and ethnic disparity, 17
- Epithelial cells, 26-27
  - barrier integrity, 23
- Epithelial permeability, 23
- Erythema, 60-62, 61
- Erythema nodosum, 42, 70t, 77-78, 78
  - in children, 43
  - incidence of, 77
- Erythrocyte sedimentation rate (ESR), 59
- Etiopathogenesis, 21-30
  - colonocytes and barrier integrity, 23, 26
  - dysbiosis, 25, 26, 212
  - environmental factors, 22-23
  - of extraintestinal manifestations, 75-76
  - family history, 21-22
  - genetic factors, 21-22
  - immunoregulatory dysfunction, 24, 26-27
  - infection with pathogens, 25
  - intestinal immune state, 25-28, 26-27
  - overview, 25-28, 26-27
  - pathogenesis (processes in), 23-25
  - susceptibility loci, 22
- Etrolizumab, 27, 201
- Exercise, 219-220
- Extensive colitis, 104t
- Extent of disease
  - categories of, 104t
  - extensive colitis, 104t
  - left-sided colitis, 37, 38, 47t, 104t
  - proctitis, 37, 38, 104t
- Extraintestinal complications, 69, 70t-74t
- Extraintestinal manifestations (EIMs), 42-43, 69, 70t-74t
  - anemia manifestations, 73t-74t, 85
  - bone manifestations, 74t, 85-86
  - in children, 43, 76
  - early diagnosis and treatment of, 69, 75, 76, 86
  - epidemiology of, 75
  - extraintestinal complications, contrasted, 69
  - genetic factors and, 76
  - hepatopancreatobiliary manifestations, 72t
  - inflammation and, 75-76
  - joint manifestations, 70t, 77
- Extraintestinal manifestations (EIMs), *continued*
  - mucocutaneous manifestations, 70t-71t, 77-79, 78-80
  - neurologic manifestations, 73t
  - occurrence prior to IBD diagnosis, 75
  - ocular manifestations, 71t, 79-80, 81
  - osteoporosis, 74t, 85-86
  - pathogenesis of, 75-76
  - in pediatric patients, 43, 76
  - prevalence of, 75
  - primary sclerosing cholangitis (PSC), 80-83, 82-84
  - prognosis and, 42
  - pulmonary manifestations, 72t-73t
  - quality of life and, 69, 86
  - renal and urologic manifestations, 73t
  - Swiss IBD Cohort Study (SIBDCS), 75
  - thromboembolic manifestations, 72t
  - treatment of, 69, 70t-74t
- Fecal calprotectin, 46t, 59, 90, 97t, 104t
- Fecal microbiota transplant (FMT), 106t, 211, 212-214
  - risks of, 213-214
    - multi-drug resistant organisms (MDRO), transfer of, 213-214
    - in treatment of *Clostridium difficile* infections, 211, 212-213
- Fistulas, 37
- Flexible sigmoidoscopy, 89-90, 107t
- Folic acid/folate
  - deficiency, 74t, 85
  - methotrexate and, 152
  - supplementation, 74t, 122, 155
- Gastroenterologists, 32, 225
  - interactions with surgeons, 203
  - knowledge about alternative treatments, 211
  - knowledge about vaccine recommendations, 230
  - patient education by, 225
  - vaccinations and, 229, 230
- Gender, and incidence of UC and CD, 17-18
- Genetic factors, 21-22
  - extraintestinal manifestations (EIMs) and, 76
  - family history, 21-22
  - susceptibility loci, 22
  - twins, 21

- Giazo (balsalazide), 112, 114, 117t  
 Goblet cell depletion, 46t  
 Golimumab (Simponi), 93-94, 161t, 178-182  
   action mechanism, 163-164, 165  
   site of action, 26  
   dosage and administration, 161t, 182  
   efficacy, 179-180, 181t, 182  
   FDA approval, 178  
   indications for, 93-94, 163, 178-179  
   safety, 180-182, 184t-185t  
     infections, 161t, 180, 184t  
     malignancy, 161t, 184t  
     warnings and precautions, 161t  
   usages, ACG recommendations, 100t, 101t  
 GRADE criteria, 96, 97t-103t  
 Gut bacteria. *See also specific bacteria.*  
   dysbiosis, 25, 26, 212  
   *E. coli* strain Nissle 1917 (EcN), 216-217  
   fecal microbiota transplant (FMT), 106t, 211, 212-214  
   in healthy gut, 23, 26, 212  
   probiotics and, 215-217  
   VSL#3, 215-216  
  
 Hadlima (adalimumab biosimilar), 201  
 Health maintenance, 225-244  
   ACG recommendations, 228t-229t  
   blood pressure screening, 236  
   cancer screening, 238-240  
   checklists, 226t-227t, 230-231  
   depression screening, 236-237  
   laboratory examinations, 240  
   ophthalmologic screening, 237  
   osteoporosis and bone mineral density, 231-236  
   patient education, 240, 241t  
   tobacco cessation, 231  
   vaccinations, 225-231, 226t-227t  
*Helicobacter hepaticus*, 25  
 Hematochezia, 104t  
 Hepatopancreatobiliary manifestations/complications, 72t  
 Hepatosplenic T cell lymphoma (HSTCL), 186  
 History/family history, 21-22  
 HLA variations, 76, 77  
  
 Hospitalizations  
   ACG recommendations, 101t-102t, 107t-108t  
   for acute severe disease, 95, 107t-108t  
     assess for toxic megacolon, 107t  
     flexible sigmoidoscopy within 24-72 hours, 107t  
     stool testing to rule of *C. difficile*, 107t  
   emergency department visits, 11  
 Human papilloma virus (HPV), 239  
 Humira. *See Adalimumab (Humira).*  
 Hydrocortisone, use in hospitalized patients, 102t  
 Hygiene Hypothesis, 33  
 Hypertension, 236  
 Hypoalbuminemia, 46t, 60  
  
 IBD. *See Inflammatory bowel disease (IBD).*  
 IL-12/23 antagonist (ustekinumab), 94, 162t, 195-200.  
   *See also Ustekinumab.*  
 Ileal-pouch anal anastomosis (IPAA), 95, 203, 206-207, 207  
 Immune response, 25-28, 26-27  
   adaptive immunity, 25-28  
 Immune state, intestinal, in healthy gut vs UC, 25-28, 26-27  
 Immunoglobulins, 24  
   IgA, IgG, IgM, 24  
 Immunomodulators, 133-158. *See also specific agents.*  
   action mechanism, 133  
   agents, 134, 136t-138t  
     cyclosporine A, 149-150  
     methotrexate, 152-155  
     tacrolimus, 151-152  
     thiopurines, 147-149  
     tofacitinib, 134-147  
   benefits of (steroid-sparing), 133  
   safety/cautions, 133, 239-240  
   usages, 133  
     ACG recommendations, 106t  
     for moderate to severe disease, 106t  
 Immunoregulatory dysfunction, 24, 26-27  
 Incidence and prevalence of IBD/UC, 9-11, 12-15, 214  
   age and, 16-17, 17  
   gender and, 17-18  
   in North America, 9-10, 12, 14  
   race/ethnicity and, 17  
   worldwide, 11, 12-15  
 Indigo carmine, 103t

- Indigo naturalis*, 218
- Induction of remission, 90, 97t-101t, 105t-106t
- Industrialization, and UC incidence, 11, 31
- Infections
- biologics and, 160t-162t, 183-186
    - adalimumab, 161t, 177t, 178
    - golimumab, 161t, 180, 184t
    - infliximab, 160t, 171, 172t
    - ustekinumab, 162t, 199
    - vedolizumab, 161t, 191, 192t, 194-195
  - differential diagnosis, 104t
  - immunomodulators and, 133
    - tofacitinib, 142-143
  - microbial exposure (Hygiene Hypothesis), 33
  - pathogenesis of UC and, 25
  - progressive multifocal leukoencephalopathy (PML), 194-195
  - tuberculosis, 186, 187
  - vaccinations and, 225-231, 226t-227t
- Inflammation
- endoscopic findings, 60-62, 61
  - pathogenesis of UC and, 23-25
  - reducing, as goal of treatment, 133
  - weight/adipose tissue and, 33-34
- Inflammatory bowel disease (IBD)
- about, 9
  - classification systems, 45-56
  - environmental risk and protective factors, 31-35
  - epidemiology of, 9-29
  - etiopathogenesis, 21-30
  - family history of, 21-22
  - incidence and prevalence, 9-11, 12-15, 214
  - morbidity and mortality, 11-16
  - resources on, 241t
  - unclassified (IBDU), 62
- Inflammatory response
- pathogenesis of, 23-25
  - triggering of, 25, 26-27
- Inflextra (infliximab biosimilar), 200
- Infliximab (Remicade), 94, 107t, 160t, 164-174
- action mechanism, 163-164, 165
  - site of action, 26
  - biosimilars, 200-201
    - Avsola, 200
    - Inflextra, 200
- Infliximab (Remicade), *continued*
- Ixifi, 200
  - Renflexis, 200
  - combination therapy, 100t, 166-170
  - dosage and administration, 160t, 171-174
  - dose escalation, 174
  - efficacy
    - adult UC, 164-170, 167, 168t-169t
    - pediatric UC, 170
  - FDA approval, 164
  - indications for, 94, 163, 164
    - adult patients, 94, 164
    - pediatric patients, 94, 164
  - safety, 171, 172t-173t
    - infections, 160t, 171, 172t
    - infusion reactions, 172t, 174
    - live vaccines, 160t
    - malignancy, 160t
    - pediatric patients, 171
    - warnings and precautions, 160t
  - usages, 163-164
    - ACG recommendations, 100t, 101t, 102t
    - in hospitalized patients, 102t
- Innate lymphoid cells (ILCs), 24, 26
- Integrin  $\alpha 4\beta 7$  blockers, 159, 161t, 187-195. See also *Vedolizumab*.
- Interleukin-12/23 antagonists, 195-200. See also *Ustekinumab*.
- Interleukins, 24, 28
- Intestinal immune state, 25-28, 26-27
- Intubation of the ileum, 104t
- Iron deficiency anemia, 46t, 60, 74t, 85
- treatment, 74t, 85
- Ischemic colitis, 56, 58t
- Ixifi (infliximab biosimilar), 200
- JAK. See *Janus kinase (JAK) family*.
- Janus kinase (JAK) family, 24, 134, 139. See also *Tofacitinib*.
- JAK inhibitor (tofacitinib), 134-137
  - JAK-STAT pathway, 24, 134, 139
- Joint manifestations, 70t, 77
- in children, 43
  - prevalence of, 42
- Laboratory investigations, 46t, 59-60, 240
- Lactoferrin, 59, 90



- Lamina propria, 26
  - mononuclear inflammation of, 46t
  - neutrophils, 64t
- Left-sided colitis, 37, 38, 47t, 104t
  - treatment options
    - aminosalicylates (5-ASAs), 91, 97t
    - ASA enemas, 91, 98t
    - combination oral/topical 5-ASA therapy, 91
    - corticosteroids, 92
- Lialda (oral mesalamine), 112, 113, 115, 118t, 120
- Lichtiger score, 55-56
- Listeria monocytogenes*, 25
- Live vaccines, 230, 234t
  - biologics and, 160t-161t
  - immunomodulators and, 133
  - recommendations for IBD patients, 230, 234t
  - TNF blockers and, 187
  - tofacitinib and, 146
  - vedolizumab and, 161t, 195
- Liver, 80-83. See also *Primary sclerosing cholangitis (PSC)*.
  - bile ducts, 81, 82-84
  - cirrhosis and failure, 81
  - hepatopancreatobiliary manifestations/complications, 72t, 80-83
  - transplant, 83
- Lymphoplasmacytosis, 63
- MAdCAM, antibody to, 27
- Maintenance of remission, 90, 101t, 107t
- Malignancies
  - biologics and, 160t-162t, 161t, 186, 239
    - adalimumab, 161t, 177t, 178
    - golimumab, 161t, 184t
    - infliximab, 160t
    - ustekinumab, 162t, 199
  - hepatosplenic T cell lymphoma (HSTCL), 186
  - tofacitinib and, 133, 146
- Management of UC, 89-110. See also *specific therapies*.
  - ACG graded recommendations, 96, 97t-103t
  - ACG key concept statements, 104t-109t
  - acute severe disease, 95, 107t-108t
  - aminosalicylate (5-ASA) therapy, 111-124
  - based on clinical severity, 89-110
  - biologics, 93-94, 159-202
    - adalimumab, 93, 174-178
  - Management of UC, *continued*
    - golimumab, 93-94, 178-182
    - infliximab, 94, 164-174
    - ustekinumab, 94, 195-200
    - vedolizumab, 94, 187-195
  - budesonide, 128-129
  - colectomy, 206-208
  - corticosteroids, 91-93, 125-132
  - cyclosporine A, 136t-137t, 149-150
  - disease extent (proctitis, left-sided colitis, extensive colitis), 104t
  - disease severity, definitions, 104t
  - goals of, 89, 97t, 104t-105t, 133
  - health maintenance and, 225-244
  - histological healing, 105t
  - hospitalized patients with acute severe UC, 107t-108t
  - immunomodulators, 133-158
  - induction of remission, 90, 97t-101t, 105t-106t
  - left-sided colitis, 91-92
  - maintenance of remission, 90, 101t, 107t
  - methotrexate, 152-155
  - mild to moderate disease, 90, 91-92, 97t-99t
  - MMX/foam (budesonide), 128-129
  - moderate to severe disease, 90, 92-94, 99t-101t, 106t-107t
  - monitoring disease activity, 89-90, 105t
  - other therapies, 211-224
    - acupuncture, massage therapy, and moxibustion, 218-219
    - complementary and alternative medicines (CAMs), 211, 214-219
    - curcumen (tumeric), 217-218
    - exercise, 219-220
    - fecal microbiota transplant (FMT), 211, 212-214
    - herbal agents, 218
    - probiotics, 215-217
    - traditional Chinese medicine (TCM), 218
    - vitamin D, 220-221
  - patient prognosis and, 96, 105t, 159
  - proctitis, 91
  - proctocolectomy, 95-96, 206-208
  - refractory or nonresponsive disease, 106t, 203, 204, 205t
  - remission, definition of, 105t
  - step-up approach, 89, 90
  - strategies, matching with goals, 104t-105t
  - surgery, 95-96, 106t, 203-210
  - tacrolimus, 151-152
  - thiopurines, 147-149

- TNF blockers, 93-94, 163-187
- tofacitinib, 93
- Massage therapy, 218-219
- Mayo score, 47-55, 49-51
  - ACG statement on, 97t
  - clinical portion, 48-50, 49
  - endoscopic subscore, 48, 49, 50-51, 50-51
  - prognosis and, 39, 41
  - UC Activity Index and, 40t
- Medical rescue therapy, 102t
- 6-Mercaptopurine, 136t, 147-149
- Mesalamine, 91, 112, 115, 117t-119t
  - formulations, 112, 115, 117t-119t
  - enema with Rowasa/SfRowasa, 112
  - oral (Apriso, Asacol HD, Delzicol, Lialda, Pentasa ), 112, 113, 115, 117t-119t
  - rectal (Canasa, Rowasa/SfRowasa), 112, 113, 115, 119t
  - for proctitis, 91
- Metalloproteinase-9 antibody, 201
- Methotrexate (MTX), 137t, 152-155
  - action mechanism, 152
  - adverse events, 154-155
  - efficacy, 152-154
  - indications for, 137t, 152
  - safety, 137t, 152-155
  - usages, 137t, 152
    - parenteral MTX, 153
    - recommendation against, for maintenance, 101t
- Methylene blue, 103t
- Methylprednisolone, use in hospitalized patients, 102t
- Microbes
  - fecal microbiota transplantation (FMT), 106t, 211, 212-214
  - in healthy gut, 23, 26, 212
  - Hygiene Hypothesis, 33
  - inflammatory response triggered by, 25, 26-27
  - probiotics, 215-217
  - VSL#3, 215-216
- Microscopic colitis, 58t
- Mild to moderate UC, management of, 90, 91-92, 97t-99t
- MMX/foam. See *Budesonide MMX*.
- Moderate UC, management of, 91-94
- Monitoring disease activity, 89-90, 105t
  - biomarkers, 90
  - colonoscopy, 89-90
  - flexible sigmoidoscopy, 89-90
- Montreal classification system, 38, 45-47, 47t, 48t
- Morbidity and mortality, 11-16
- Mortality, 11-16
- Moxibustion, 218-219
- Mucin depletion, 46t
- Mucocutaneous manifestations/complications, 70t-71t, 77-79, 78-80
- Mucosa
  - chronic mucosal injury, 63
  - control of mucosal inflammation, 105t
  - endoscopic features in UC, 46t, 60-62, 61
  - inflammatory cell infiltration, 63, 64t-65t
- Multiple organ dysfunction syndrome (MODS), 95
- Musculoskeletal manifestations/complications, 70t
- MUTAFLOR (*E. coli* strain Nissle 1917), 216-217
- Mycobacterium paramyxovirus*, 25
- Mycobacterium paratuberculosis*, 25
- Nancy histological index, 64t
- Natalizumab (Tysabri), 194
- National Institute of Diabetes and Digestive and Kidney Diseases, 241t
- Nephritis, 73t
- Nephrolithiasis, 73t
- Neurologic manifestations/complications, 73t
- Neutrophils, 64t-65t
- Night-blindness, 71t
- NSAIDs, recommendation to avoid in acute severe UC, 107t
- Nuclear factor kappaB (NF-κB), 24, 111
- Occupation, 33
- Ocular manifestations/complications, 42, 71t, 79-80, 237
  - conjunctivitis, 79
  - corticosteroid use and, 237
  - glaucoma/cataract, 71t, 237
  - night-blindness, 71t
  - ophthalmologic screening, 237
  - scleritis and episcleritis, 71t, 79-80, 237
  - uveitis, 71t, 80, 81, 237
- Older adults
  - clinical presentation in, 41
  - elderly-onset IBD, 41
  - symptoms in, 41
- Olsalazine (Dipentum), 91, 112, 114, 116t
- Ophthalmologic screening, 237

- Opioids, recommendation to avoid in acute severe UC, 107t
- Osteonecrosis, 74t
- Osteopenia, 74t, 235
- Osteoporosis, 74t, 85-86, 231-236
  - bisphosphonates for, 235
  - in children, 43
  - corticosteroid use and, 235
  - risk factors, 235
  - secondary, 235-236
  - treatment of, 85-86
- Pancolitis, 37
  - backwash ileitis in, 62
  - in pediatric patients, 41
- Pancreas
  - bile ducts, 81, 82-84
  - hepatopancreatobiliary manifestations/complications, 72t
  - pancreatitis in children, 43
- Paneth cells, 63
- Parasite-induced colitis, 56, 58t
- Paris classification system, 46-47, 48t
- Patchy disease, 62
- Pathogenesis of UC, 21-30. See also *Etiopathogenesis*.
  - colonocytes and barrier integrity, 23, 26
  - dysbiosis, 25, 26, 212
  - of extraintestinal manifestations, 75-76
  - genetic factors, 21-22
  - immunoregulatory dysfunction, 24, 26-27
  - infection, 25
  - intestinal immune state, 25-28, 26-27
- Patient assessment, 89-90
- Patient compliance, 89-90
  - aminosalicylate (5-ASA) therapy, 19, 113-120
  - complementary and alternative medicines (CAMs) and, 214
  - enemas and, 91
- Patient education, 240, 241t
- Patient prognosis, as consideration in treatment choice, 96, 105t, 159
- Patients, including in decision-making, 90
- Pediatric patients
  - atypical features in, 62-63
  - extraintestinal manifestations (EIMs) in, 43, 76
  - infliximab use in, 94, 164, 171
  - pancolitis in, 41
- Pediatric Ulcerative Colitis Activity Index (PUCAI), 41, 56, 57t
- Pentasa (oral mesalamine), 112, 113, 115, 118t
- Peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ), 24, 111
- Physical examination, 37
- Plasma cells, 63
- PML (progressive multifocal leukoencephalopathy), 194-195
- Pouchitis, 208
- PPAR- $\gamma$ , 24, 111
- Prednisone
  - dosages and usages, 102t
  - for left-sided colitis, 92
  - for moderate to severe disease, 93
- Prevalence of UC, 9-11, 12-15. See also *Incidence and prevalence of IBD/UC*.
- Prevention of colorectal cancer. See *Colorectal cancer prevention in UC*.
- Primary care clinicians, 225
  - vaccinations and, 229
- Primary sclerosing cholangitis (PSC), 42, 80-83, 82-84
  - cancer risk and, 42, 238
  - in children, 43
  - diagnosis, 81, 83-84
  - “onion skin” pattern, 82, 84
  - prevalence of, 42
  - symptoms, 81
- Probiotics, 106t, 215-217
- Proctitis, 37, 38, 104t
  - aminosalicylates (5-ASAs) for, 91, 97t
  - mesalamine for, 91
  - topical steroids for, 91
- Proctocolectomy, 95, 203, 206-207, 207. See also *Surgery*.
- Proctosigmoiditis, 37, 38
- Prognosis, 39-41
  - ACG key concept statements on, 104t
  - as consideration in treatment choice, 96, 105t, 159
  - extraintestinal manifestations and, 42
- Progression of UC, 37, 39
- Progressive multifocal leukoencephalopathy (PML), 194-195
- Protective factors, 31-36
  - appendectomy, 31
  - microbial exposure (Hygiene Hypothesis), 33
  - tobacco smoking, 31-32, 231
- PSC. See *Primary sclerosing cholangitis (PSC)*.
- Psoriasis, 77
- PUCAI (Pediatric Ulcerative Colitis Activity Index), 41, 56, 57t

- Pulmonary manifestations/complications, 72t-73t
- Pyoderma gangrenosum, 42, 70t, 78-79, 79
  - in children, 43
  - incidence of, 77, 78
- Quality of life
  - extraintestinal manifestations and, 69, 86
  - as goal of treatment, 89
  - surgery and, 203
- Race and ethnicity, 17
- Reactive oxygen species, 111
- Rectal administration of medications
  - enemas, 98t, 112, 113
    - with Rowasa/SfRowasa (mesalamine), 112
  - enemas versus suppositories, 113, 114
  - suppositories, 91
    - Canasa (mesalamine), 113
- Rectal bleeding, 46t
  - Mayo score and, 48, 49
- Rectal examination, 37
- Rectal sparing, 62
- Remicade. *See* *Infliximab (Remicade)*.
- Remission
  - deep remission, 105t
  - definition of, 105t
  - induction of remission, 90, 97t-101t, 105t-106t
  - maintenance of remission, 90, 101t, 107t
  - symptomatic remission, 105t
- Renal and urologic manifestations/complications, 73t
- Renflexis (infliximab biosimilar), 200
- Reversible posterior leukoencephalopathy syndrome (RPLS), 199-200
- Risk
  - environmental risks, 22-23, 31-36
  - genetic loci and, 22
  - protective factors, 31-36
- Robarts histopathology index, 64t-65t
- Rome classification system, 45
- Rowasa/SfRowasa (rectal mesalamine), 112, 115, 118t
- RPLS (reversible posterior leukoencephalopathy syndrome), 199-200
- Saccharomyces cerevisiae* (anti-*S. cerevisiae* antibody, ASCA), 60
- Sacroiliitis, 77
- Scleritis and episcleritis, 71t
- Severity of UC, 37-39, 38, 89-110, 159. *See also* *Extent of disease*.
  - ACG UC Activity Index, 39, 40t
  - acute severe disease, 95
  - classification systems and, 38
  - disease management based on, 89-110
  - endoscopic evaluation, 60-62, 61
  - mild to moderate UC, 90, 91-92, 97t-99t
  - moderate to severe UC, 90, 92-94, 99t-101t, 106t-107t
  - Montreal classification, 38, 46-47, 47t, 48t
  - severe UC, 90
  - severity indexes, 40t, 47-55, 57t, 64t-65t
  - step-up approach to treatment, 89, 90
  - Ulcerative Colitis Endoscopic Index of Severity (UCEIS), 51-55, 52-54
  - ulcerative proctitis, 37, 38
- Signal transducers and activators of transcription (STATs), 24, 139
- Simple Clinical Colitis Activity Index, 56
- Simponi. *See* *Golimumab (Simponi)*.
- Skin cancer screening, 239-240
- Skin manifestations of UC, 42, 70t-71t, 77-79, 78-80
- Sleep disruption, 34
- Smoking (tobacco smoking), 31-32, 231
- Sphingosine-1 phosphate receptor modulators (S1P1), 201
- Stelara. *See* *Ustekinumab (Stelara)*.
- Step-up approach to treatment, 89, 90
- Steroids. *See* *Corticosteroids*.
- Stool biomarkers, 59, 90
- Stool frequency, 107t
  - Mayo score, 48, 49
- Stool lactoferrin, 59, 90
- Stool testing/studies, 56-59
  - ACG recommendations, 97t
- Strictures
  - bile duct, in PSC, 81, 82, 83, 84
  - stricture formation as indication for surgery, 96, 205t, 206
- Sulfasalazine, 91, 111-112, 114, 116t
  - adverse reactions, 91, 111, 122
  - folic acid supplementation and, 122
- Suppositories, mesalamine (Canasa), 112, 113
- Surgery, 95-96, 203-210
  - complications of, 207-208
  - delays in, complications and mortality, 95
  - indications for, 95-96, 204-206, 205t
    - acute severe disease, 95, 204

- colorectal cancer, 205t, 206
- elective proctocolectomy, 203
- refractory or nonresponsive disease, 106t, 203, 204, 205t
- stricture formation, 205t, 206
- toxic megacolon, 95, 108t, 204, 205t
- urgent, emergent, or elective, 205t
- proctocolectomy, 95, 203, 206-207, 207
  - stages of, 206-207, 207
- quality of life and, 203
- rates/incidence of surgeries, 203-204
- risk, for IBD patients, 11-16
- in step-up approach to treatment, 90, 90
- timing of evaluation for, 95, 107t
- total proctocolectomy with ileal-pouch anal anastomosis (IPAA), 95, 203, 206-207, 207
- Sweet syndrome, 70t, 77, 79
- Swiss IBD Cohort Study (SIBDCS), 75
- Symptomatic remission, 105t
- Symptoms of UC, 9, 37, 38
  - in children, 41
  - in older adults, 41
- Systemic involvement in UC and CD, 69
- Systemic medications
  - corticosteroids, 106t
  - endoscopic findings and, 62
- T cells, 25-28, 26-27
  - differentiation, 27
  - hepatosplenic T cell lymphoma (HSTCL), 186
  - homing, 27
  - subtypes of, 25-28
- Tacrolimus, 137t, 151-152
  - action mechanism, 151
  - efficacy, 151
  - indications for, 137t
  - safety, 137t, 151-152
  - usages, 137t, 151
- Thiopurines (azathioprine and 6-mercaptopurine), 136t, 147-149
  - action mechanism, 147
  - combination therapy, 100t, 148
  - efficacy, 147-148
  - indications, 136t, 147-148
    - for moderate to severe disease, 90, 93, 101t
  - safety, 136t, 148-149
- Thiopurines (azathioprine and 6-mercaptopurine), *continued*
  - usages, 126t, 147
    - ACG recommendations, 100t, 101t
    - in hospitalized patients, 102t
    - in step-up approach to treatment, 90
- Thrombocytosis, 46t
- Thromboembolism, 42, 72t
  - prophylaxis for preventions, 72t, 102t
  - tofacitinib and, 146
- Tight junctions, 23
- Tobacco smoking, 31-32, 231
- Tofacitinib (Xeljanz/Xeljanz XR), 134-147, 136t
  - action mechanism, 134, 139
    - site of action, 26
  - combination therapy, cautions for, 93
  - dosage and administration, 146-147
  - efficacy, 135-142, 140, 141
    - OCTAVE trials, 135-142, 140, 141
  - FDA approval for UC, 93, 134
  - indications, 136t
    - for moderate to severe disease, 90, 93
  - safety, 136t, 142-146, 144t-145t
    - infections, 133, 142-143
    - malignancies, 133, 146
    - thrombosis, 146
    - viral reactivation, 143-146
    - warnings and precautions, 143-146
  - usages, 93, 134, 136t
    - ACG recommendations, 100t, 101t
    - in step-up approach to treatment, 90
- Topical medications, endoscopic findings and, 62
- Total parental nutrition, AGU recommendations, 101t, 102t
- Toxic megacolon, 60, 95
  - assessment for, 107t
    - as indication for surgery, 95, 108t, 204, 205t
- Traditional Chinese medicine (TCM), 218
- Treatment. *See Management of UC.*
- TREM-1, 23
- Truelove and Witts severity index, 55
- Tuberculosis, TNF blockers and, 186, 187
- Tumor necrosis factor $\alpha$  (TNF $\alpha$ ), 28, 164, 165
- Tumor necrosis factor (TNF) blockers, 93-94, 160t-161t, 163-187.

See also *specific agents*.

- action mechanism, 163-164, 165
- for acute severe disease, 95
- agents
  - adalimumab, 93, 161t, 174-178
  - golimumab, 93-94, 161t, 178-182
  - infliximab, 94, 160t, 164-174
- therapeutic drug monitoring, 183
- usages
  - ACG recommendations, 100t-101t, 106t
  - alternate therapy with another TNF blocker, 106t
  - for moderate to severe disease, 100t-101t, 106t
  - suggestion against adding 5-ASA, 100t
  - trying other mechanisms/drugs in case of loss of efficacy, 106t
- warnings and precautions, 160t-162t, 182-187
  - hypersensitivity reactions, 187
  - infections, 183-186
  - live vaccines, 187
  - malignancies, 186, 239
  - tuberculosis, 186
- Twins, 21
- Tyrosine kinases (JAK kinases), 24, 134, 139
- Tysabri (natalizumab), 194

UCEIS. See *Ulcerative Colitis Endoscopic Index of Severity*.

Uceris. See *Budesonide (Uceris)*.

Ulcerative Colitis Endoscopic Index of Severity (UCEIS), 51-55, 52-54

Ulcerative Colitis (UC)

- as chronic disease, 9, 11, 21, 104t
- clinical presentation, 37-44
- costs of care, 10
- course of disease, 37, 39
- environmental factors and risks, 31-36
- epidemiology, 9-29
- incidence and prevalence of, 9-11, 12-15
- morbidity and mortality, 11-16
- pathogenesis of, 21-30
- resources on, 241t
- symptoms, 9, 37, 38
- treatment. See *Management of UC*.
- Ulcerative proctitis, 37, 38, 47t
- Upper GI tract involvement, 62
- Urologic manifestations/complications, 73t

- Ustekinumab (Stelara), 94, 162t, 195-200
  - action mechanism, 195-196, 196
  - dosage and administration, 162t, 200
  - efficacy, 196-197, 198
  - indications for, 94, 163, 195
  - safety, 197-200
    - infections, 162t, 199
    - malignancies, 162t, 199
    - reversible posterior leukoencephalopathy syndrome (RPLS), 199-200
    - warnings and precautions, 162t, 199-200
- Uveitis, 71t, 80, 81, 237
- Vaccinations, 225-231. See also *Live vaccines*.
  - checklists, 226t-227t, 230-231
  - human papilloma virus (HPV), 239
  - live vaccines, 133, 160t-161t, 187, 230, 234t
  - non-live vaccines, 230, 232t-233t
- Vancomycin, 102t
- Vasculitis, 77
- Vedolizumab (Entyvio), 94, 161t, 187-195
  - action mechanism, 187-188, 188
  - site of action, 27
  - dosage and administration, 161t, 195
  - efficacy, 189-191, 190t
  - FDA approval, 188
  - indications for, 94, 95, 163, 188
    - acute severe disease, 95
  - safety, 191-195, 192t-193t
    - infections, 161t, 191, 192t, 194-195
    - infusion reactions, 192t, 194
    - live vaccines, 161t, 195
    - progressive multifocal leukoencephalopathy (PML), 194-195
    - warnings and precautions, 161t, 194-195
  - usages, 188
    - ACG recommendations, 100t, 101t
    - in hospitalized patients, 102t
- Venous thromboembolism, 42
- Vienna classification system, 45
- Viral or parasite-induced colitis, 56, 58t
- Vitamin B12
  - deficiency, 74t, 85
  - supplementation, 74t

Vitamin D, 74t, 85, 220-221  
deficiency, 220-221  
supplementation, 74t, 86, 128, 221  
VSL#3, 215-216

Weight, 33-34

Xeljanz/Xeljanz XR. See *Tofacitinib*.